Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) PT at $30.25

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned an average rating of “Buy” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $30.25.

A number of analysts have weighed in on the stock. Bank of America dropped their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Morgan Stanley dropped their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $18.00 to $24.00 in a report on Wednesday, February 26th.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Yasunori Kaneko bought 20,000 shares of the stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the purchase, the director now owns 28,400 shares in the company, valued at $285,704. This trade represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arcus Biosciences

Large investors have recently bought and sold shares of the stock. R Squared Ltd bought a new position in shares of Arcus Biosciences during the 4th quarter valued at about $26,000. Point72 Hong Kong Ltd bought a new position in shares of Arcus Biosciences during the 3rd quarter valued at about $47,000. Lazard Asset Management LLC boosted its position in shares of Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after purchasing an additional 6,078 shares in the last quarter. US Bancorp DE boosted its position in shares of Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares in the last quarter. Finally, Quest Partners LLC boosted its position in shares of Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Trading Down 1.4 %

NYSE RCUS opened at $8.95 on Friday. Arcus Biosciences has a 12 month low of $8.82 and a 12 month high of $19.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The company has a market capitalization of $940.46 million, a price-to-earnings ratio of -2.84 and a beta of 1.36. The company’s fifty day moving average price is $11.66 and its two-hundred day moving average price is $14.62.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million for the quarter, compared to analysts’ expectations of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. As a group, research analysts predict that Arcus Biosciences will post -3.15 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.